Ariosa Diagnostics, Sequenom diagnostic news
Sequenom filed a notice of appeal in the U.S. Court of Appeals for the Federal Circuit of a lower court's order denying a motion for preliminary injunction to prevent Ariosa (formerly Aria Diagnostics Inc.) from marketing its Harmony Prenatal Test. Earlier this month, the U.S. District Court for the Northern District of California denied the motion filed by Sequenom alleging that the sale of the test infringes its U.S. Patent No. 6,258,540, which covers prenatal diagnosis using nucleic acid analysis used in Sequenom's MaterniT21 Plus laboratory-developed test (LDT) and expires in 2018. Last December, Ariosa filed an action in the court against Sequenom, seeking declaratory relief that its Harmony test does not infringe any claims of the '540 patent. Sequenom filed a counterclaim asserting that Ariosa infringed the patent (see BioCentury, July 16). ...